Nuvigil NDA On Schedule For First Quarter; Cephalon Touts Duration of Action
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cephalon on track to file its insomnia agent Nuvigil during the first quarter, firm says